Recent outbreaks of Andes virus hantavirus have highlighted the absence of approved vaccines for New World strains causing hantavirus pulmonary syndrome, yet all candidates remain in preclinical or early Phase 1/2 stages. mRNA platforms from Moderna and Korea University collaborations, along with DNA and viral-vector approaches, show promise in animal models but require years of human safety, immunogenicity, and efficacy trials plus regulatory review before any 2026 licensure. Standard development timelines, absent emergency acceleration akin to Operation Warp Speed, support the 93% market-implied probability of no vaccine. Faster progress could occur with unexpected funding surges or trial breakthroughs, though model consensus indicates low likelihood before 2027 or later.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$116,017 交易量
$116,017 交易量
2026-12-31
$116,017 交易量
$116,017 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent outbreaks of Andes virus hantavirus have highlighted the absence of approved vaccines for New World strains causing hantavirus pulmonary syndrome, yet all candidates remain in preclinical or early Phase 1/2 stages. mRNA platforms from Moderna and Korea University collaborations, along with DNA and viral-vector approaches, show promise in animal models but require years of human safety, immunogenicity, and efficacy trials plus regulatory review before any 2026 licensure. Standard development timelines, absent emergency acceleration akin to Operation Warp Speed, support the 93% market-implied probability of no vaccine. Faster progress could occur with unexpected funding surges or trial breakthroughs, though model consensus indicates low likelihood before 2027 or later.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$116,017结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Recent outbreaks of Andes virus hantavirus have highlighted the absence of approved vaccines for New World strains causing hantavirus pulmonary syndrome, yet all candidates remain in preclinical or early Phase 1/2 stages. mRNA platforms from Moderna and Korea University collaborations, along with DNA and viral-vector approaches, show promise in animal models but require years of human safety, immunogenicity, and efficacy trials plus regulatory review before any 2026 licensure. Standard development timelines, absent emergency acceleration akin to Operation Warp Speed, support the 93% market-implied probability of no vaccine. Faster progress could occur with unexpected funding surges or trial breakthroughs, though model consensus indicates low likelihood before 2027 or later.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$116,017结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Recent outbreaks of Andes virus hantavirus have highlighted the absence of approved vaccines for New World strains causing hantavirus pulmonary syndrome, yet all candidates remain in preclinical or early Phase 1/2 stages. mRNA platforms from Moderna and Korea University collaborations, along with DNA and viral-vector approaches, show promise in animal models but require years of human safety, immunogenicity, and efficacy trials plus regulatory review before any 2026 licensure. Standard development timelines, absent emergency acceleration akin to Operation Warp Speed, support the 93% market-implied probability of no vaccine. Faster progress could occur with unexpected funding surges or trial breakthroughs, though model consensus indicates low likelihood before 2027 or later.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题